Huntingtin Protein

Overview

<table class=“infobox infobox-protein”> <tr> <th class=“infobox-header” colspan=“2”>Huntingtin Protein</th> </tr> <tr> <td class=“label”>Agent</td> <td>Target</td> </tr> <tr> <td class=“label”>Tominersen</td> <td>HTT ASO</td> </tr> <tr> <td class=“label”>ASO-HTTRx</td> <td>HTT</td> </tr> <tr> <td class=“label”>others</td> <td>Various</td> </tr> <tr> <td class=“label”>Partner</td> <td>Interaction Type</td> </tr> <tr> <td class=“label”>HAP40</td> <td>Protein binding</td> </tr> <tr> <td class=“label”>BDNF</td> <td>Transcriptional regulation</td> </tr> <tr> <td class=“label”>CBP/p300</td> <td>Transcription</td> </tr> <tr> <td class=“label”>RAB11</td> <td>Vesicle transport</td> </tr> <tr> <td class=“label”>p53</td> <td>Apoptosis regulation</td> </tr> </table>

Huntingtin Protein is a protein that huntingtin is essential for embryonic development and has multiple functions in the adult nervous system[1]:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target. [@huntingtin2020]

Structure

Huntingtin (HTT) is one of the largest known proteins, with 3,144 amino acids in the canonical isoform. It is characterized by several structural features[1]:

Domain Architecture

• N-terminal domain (1-90 aa): Contains the polyglutamine (polyQ) tract (CAG repeat, normally 10-35)
• HEAT repeat domain (90-1,700 aa): ~23 HEAT repeats; mediates protein-protein interactions
• Bridge region (1,700-2,200 aa): Flexible linker with multiple proline-rich motifs
• C-terminal domain (2,200-3,144 aa): Contains additional HEAT repeats and regulatory sequences

The HEAT repeats form alpha-helical solenoids that mediate interactions with numerous partner proteins. The polyQ tract length determines pathogenicity—expansion beyond ~36 repeats causes Huntington’s disease[1].

Post-Translational Modifications

• Phosphorylation: At Ser-16, Ser-421, Thr-47 (neuroprotective)
• Acetylation: At Lys-44, Lys-555 (affects aggregation and clearance)
• Sumoylation: Multiple sites
• Palmitoylation: At Cys-214 (membrane association)
• Proteolytic cleavage: By caspases, calpains generating toxic N-terminal fragments

Normal Function

Huntingtin is essential for embryonic development and has multiple functions in the adult nervous system[1]:

Vesicle Trafficking

• Axonal transport: Associates with dynein/dynactin and kinesin for vesicle movement
• Synaptic vesicle function: Regulates neurotransmitter release
• Endocytic pathway: Involved in receptor trafficking

Gene Expression Regulation

• Transcriptional co-activator: Interacts with p53, NF-κB, and other transcription factors
• Chromatin remodeling: Associates with histone acetyltransferases (CBP, p300)
• BDNF transcription: Positively regulates BDNF expression

Cellular Protection

• Anti-apoptotic function: Sequesters pro-apoptotic proteins
• Mitochondrial function: Supports mitochondrial dynamics and quality
• Autophagy regulation: Involved in selective autophagy

Developmental Functions

• Early development: Essential for gastrulation
• Neuronal survival: Supports cortical and striatal neuron viability
• Synapse formation: Regulates dendritic spine development

Role in Neurodegeneration

Huntington’s Disease (HD)

CAG repeat expansion (≥36 repeats) causes autosomal dominant Huntington’s disease[1]:

Pathogenic Mechanisms

• Toxic gain of function: Mutant HTT forms aggregates in neurons[2]
• Loss of normal function: Disrupted protein interactions[2]
• Transcriptional dysregulation: Altered gene expression patterns[2]
• Mitochondrial dysfunction: Energy deficit and oxidative stress[2]
• Axonal transport defects: Impaired vesicle trafficking

Neuropathology

• Striatal degeneration: Medium spiny neurons particularly vulnerable
• Cortical atrophy: Progressive loss of cortical volume
• HTT inclusions: Mutant protein aggregates throughout brain
• White matter changes: Demyelination and axonal loss

Systemic Features

• Peripheral manifestations: Muscle wasting, metabolic changes
• Cognitive decline: Executive dysfunction, eventually dementia
• Psychiatric symptoms: Depression, anxiety, psychosis

Role in Other Neurodegenerative Diseases

• Alzheimer’s disease: HTT may interact with APP and tau
• Parkinson’s disease: Altered autophagy in PD linked to HTT
• ALS: HTT inclusions in some ALS cases

Mechanisms of Toxicity

1. Aggregate formation: Toxic oligomers and inclusions
2. Transcriptional dysregulation: Sequestration of transcriptional co-activators
3. Mitochondrial dysfunction: Impaired energy metabolism
4. Axonal transport disruption: Loss of neurotrophic support
5. Synaptic failure: Impaired neurotransmitter release

Therapeutic Targeting

Gene Silencing Approaches

• Antisense oligonucleotides (ASOs): Multiple clinical trials (e.g., Tominersen, others)
• RNAi and CRISPR: Under development
• Allele-specific targeting: Targeting mutant allele specifically

Protein-Targeting Strategies

• Aggregation inhibitors: Small molecules to prevent aggregation
• HTT phosphorylation: Modulating protective phosphorylation sites
• Proteostasis enhancement: Autophagy inducers

Symptomatic Treatments

• Motor symptoms: Tetrabenazine, VMAT2 inhibitor
• Cognitive dysfunction: Under investigation
• Psychiatric symptoms: Standard treatments

Disease Modification

• Neuroprotective strategies: BDNF enhancement, mitochondrial protectants
• Cell replacement therapy: Stem cell approaches under investigation
• Gene therapy: AAV-delivered gene silencing

Clinical Trials

Protein Interactions

See Also

• Alzheimer’s Disease
• Parkinson’s Disease

External Links

• PubMed
• KEGG Pathways

References

1. Unknown, Huntingtin structure and function (Cell 2020) (2020)
2. Unknown, Huntington’s disease pathogenesis (Nat Rev Neurosci 2021) (2021)